文 献6）Yano M, Tsujinaka T, Shiozaki H, Inoue M, Doki Y, Yamamoto M, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol 1999; 70(1): 25-32.7）Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. PhaseⅡstudy of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer 2016; 115(11): 1328-34.8）Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol 2020; 27(2): 460-7.9）Hagi T, Makino T, Yamasaki M, Tanaka K, Nishida N, Sakai D, et al. Dysphagia score as a predictor of adverse events due to triplet chemotherapy and oncological outcomes in 434 consecutive patients with esophageal cancer. Ann Surg Oncol 2019; 26(13): 4754-64.10) Sugimura K, Miyata H, Tanaka K, Makino T, Takeno A, Shiraishi O, et al. Multicenter randomized phase 2 trial comparing chemoradiotherapy and docetaxel plus 5-fluorouracil and cisplatin chemotherapy as initial induction therapy for subsequent conversion surgery in patients with clinical T4b esophageal cancer: short-term results. Ann Surg 2021; 274(6): e465-e472.161）Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, et al. Multicenter randomized phaseⅡstudy of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol 2017; 28(1): 116-20.2）Sugimura K, Miyata H, Shinno N, Ushigome H, Asukai K, Yanagimoto Y, et al. Prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant docetaxel/cisplatin/5-fluorouracil followed by surgery. Oncology 2019; 97(6): 348-55.3）Makino T, Yamasaki M, Miyazaki Y, Wada N, Takahashi T, Kurokawa Y, et al. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Dis Esophagus 2018; 31(4). doi: 10.1093/dote/dox1304）Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol 2012; 106(4): 441-7.5）Ishikawa K, Nakamatsu K, Shiraishi O, Yasuda T, Nishimura Y. Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer. Int J Clin Oncol 2015; 20(3): 531-7.
元のページ ../index.html#30